Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FRYL
REST API REST API
Homo sapiens
FRYL is differentially expressed in 307 experiments: 142 organism parts: liver, hypothalamus, ... (140 more);, 220 disease states: normal, control, ... (218 more);, 106 cell types 345 cell lines 41 compound treatments and 68 other conditions.
Synonyms DKFZp686E205, KIAA0826
Orthologs FRYL (Gallus gallus)   fryl (Danio rerio)   Fryl (Mus musculus)   TAO3 (Saccharomyces cerevisiae)   ENSCING00000014937 (Ciona intestinalis)   ENSCING00000009278 (Ciona intestinalis)   FRYL (Bos taurus)   fry (Drosophila melanogaster)   RGD1311309 (Rattus norvegicus)   fryl (Xenopus laevis)   FRYL (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, binding
UniProt Accession D6R9B9, D6RJI4, O94915, F5GX82, F2Z2S2
Search EB-eye ENSG00000075539
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-1577, E-GEOD-3526, E-MTAB-62, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (41 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
SW480
3
E-MTAB-37, E-GEOD-18005, E-GEOD-2509
MCF7
2
E-MTAB-37, E-GEOD-5258
MCF-10A
2
E-TABM-420, E-GEOD-14990
T84
2
E-MTAB-37, E-GEOD-1474
MKN45
1
E-GEOD-15460
339 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21750, ... (51 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
eosinophil
1
E-GEOD-3982
effector memory T cell
1
E-GEOD-3982
adipose tissue-derived stem cell
1
E-MEXP-872
100 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (71 experiments)

Factor Value U/D Experiments
pancreatic carcinoma
2
E-MEXP-1121, E-MTAB-37
benign prostatic hyperplasia
2
E-MEXP-1243, E-GEOD-7307
colorectal adenocarcinoma
2
E-AFMX-5, E-MTAB-62
lung adenocarcinoma
2
E-MEXP-231, E-GEOD-2514
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
214 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-697, ... (29 experiments)

Factor Value U/D Experiments
none
3
6
E-GEOD-5824, E-GEOD-1417, E-GEOD-412, E-GEOD-2803, E-TABM-868, ... (9 experiments)
NaOH
1
E-MEXP-2590
filtered air
1
E-TABM-127
granulocyte-colony stimulating factor
1
E-GEOD-7400
selenium
1
E-MEXP-1327
resveratrol
1
E-TABM-782
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-1140, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-GEOD-6236, E-GEOD-7307, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-2509, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-17476, E-MEXP-421, E-TABM-868, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-21612, E-TABM-127, E-GEOD-20540, E-MEXP-1446, E-GEOD-10315, ... (8 experiments)

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-TABM-740, E-MEXP-2069, E-MEXP-1648, E-TABM-15, ... (32 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, E-MEXP-1403

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-7540, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561

Processing time: 0.472 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM